In August 2022, the Company entered into a commercial supply agreement with Otsuka to: (i) supply LUPKYNIS inventory to Otsuka at cost plus a margin; and (ii) provide manufacturing and other services…
Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or …
Aurinia Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AUPH-DEBT
Debt stack $68.6M
90%
Market cache reports total debt of $68.6M.
AUPH-DEBT-7974
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2022-12-31.
Aurinia Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aurinia Pharmaceuticals Inc..
Aurinia Pharmaceuticals Inc. Ownership
Holder
Name
Confidence
Evidence
AUPH-OWNER-TANG-CAPITAL-MANAGEMENT-LLC
TANG CAPITAL MANAGEMENT LLC
90%
13F overlay lists TANG CAPITAL MANAGEMENT LLC as top holder; 261 tracked holders.
Aurinia Pharmaceuticals Inc. Extended Supply Chain Network